{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T11:05:51Z","timestamp":1766574351798,"version":"3.48.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Health Qual Life Outcomes"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pancreatic cancer has an aggressive nature, and treatment severely impacts patients\u2019 quality of life. There is limited understanding how patients weigh treatment benefits against side effects, which hampers the development of patient-centered care and shared decision-making programs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Two discrete-choice surveys were designed: one comprising pancreatic cancer patients with (borderline) resectable disease (early-stage disease), and one including patients with non-resectable or metastatic disease (late-stage disease). Relevant criteria for describing treatments were identified by literature review and validated through patient and expert interviews. Selected criteria were likelihood of adverse events causing hospitalization, impact on daily functioning, gastrointestinal symptoms, life expectancy and frequency of hospital visits. Interim analysis was executed after 109 inclusions, optimizing the choice task combinations. Patients were recruited from a local center and a nationwide questionnaire project.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, 428 surveys were sent out and 53% of the participants answered at least one choice task. This included 165 participants with early-stage disease and 62 participants with late-stage disease. Most participants had treatment experience before completing the survey. For both disease stages, participants had a significant preference for the treatment options instead of receiving best supportive care only, although there was significant heterogeneity for this preference among the participants. Life expectancy was the most important treatment characteristic of the pre-selected criteria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Pancreatic cancer patients, both with early-stage and late-stage disease, choose for anti-cancer treatment over best supportive care and value life expectancy as the most important treatment attribute, although significant differences exist between patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12955-025-02440-5","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T10:04:09Z","timestamp":1766570649000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patient preferences for pancreatic cancer treatment (PERSEUS): a multicenter discrete choice experiment"],"prefix":"10.1186","volume":"23","author":[{"given":"Marjolein F.","family":"Lansbergen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian P.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evelien N.","family":"van Alphen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Augustinus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilse J. M.","family":"Fransen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna W.","family":"Wilmink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc G.","family":"Besselink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I. Quintus.","family":"Molenaar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marjolein Y. V.","family":"Homs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignace H. J. T.","family":"de Hingh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bert. A.","family":"Bonsing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith de","family":"Vos \u2013 Geelen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brigitte C. M.","family":"Haberkorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pauline A. J.","family":"Vissers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pythia T.","family":"Nieuwkerk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maarten F.","family":"Bijlsma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geert W. J.","family":"Frederix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanneke W. M.","family":"van Laarhoven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"for the Dutch Pancreatic Cancer Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,24]]},"reference":[{"key":"2440_CR1","unstructured":"Integraal Kankercentrum Nederland. Overleving HPB-tumoren iknl.nl. 2019 [Available from: https:\/\/www.iknl.nl\/kankersoorten\/hpb-tumoren\/registratie\/overleving: IKNL."},{"issue":"46","key":"2440_CR2","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s12029-015-9724-1","volume":"3","author":"A Carrato","year":"2015","unstructured":"Carrato A, et al. A systematic review of the burden of pancreatic cancer in europe: real-world impact on survival, quality of life and costs. Gastrointest Cancer. 2015;3(46):201\u201311.","journal-title":"Gastrointest Cancer"},{"issue":"6","key":"2440_CR3","doi-asserted-by":"publisher","first-page":"704","DOI":"10.6004\/jnccn.2020.7528","volume":"18","author":"TM Mackay","year":"2020","unstructured":"Mackay TM, et al. Patient satisfaction and quality of life before and after treatment of pancreatic and periampullary cancer: a prospective multicenter study. J Natl Compr Canc Netw. 2020;18(6):704\u201311.","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"2440_CR4","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1097\/SLA.0000000000002633","volume":"270","author":"L Rijssen","year":"2019","unstructured":"Rijssen L, et al. Core set of patient-reported outcomes in pancreatic cancer (COPRAC): an international Delphi study among patients and health care providers. Annal Of Surg. 2019;270(1):158\u201364.","journal-title":"Annal Of Surg"},{"issue":"4","key":"2440_CR5","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1097\/MPA.0000000000001025","volume":"47","author":"MR Bauer","year":"2018","unstructured":"Bauer MR, et al. Quality of life in patients with pancreatic cancer and their caregivers: a systematic review. Pancreas. 2018;47(4):368\u201375.","journal-title":"Pancreas"},{"key":"2440_CR6","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ejca.2019.11.002","volume":"125","author":"AEJ Latenstein","year":"2020","unstructured":"Latenstein AEJ, van der Geest LGM, Bonsing BA, Groot Koerkamp B, Haj Mohammad N, de Hingh I, et al. Nationwide trends in incidence, treatment and survival of pancreatic ductal adenocarcinoma. Eur J Cancer. 2020;125:83\u201393.","journal-title":"Eur J Cancer"},{"issue":"4","key":"2440_CR7","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1001\/jamasurg.2023.7872","volume":"159","author":"TM Mackay","year":"2024","unstructured":"Mackay TM, Latenstein AEJ, Augustinus S, van der Geest LG, Bogte A, Bonsing BA, et al. Implementation of best practices in pancreatic cancer care in the Netherlands: a stepped-wedge randomized clinical trial. JAMA Surg. 2024;159(4):429\u201337.","journal-title":"JAMA Surg"},{"issue":"1","key":"2440_CR8","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1245\/s10434-023-14375-6","volume":"31","author":"LV Saadat","year":"2024","unstructured":"Saadat LV, Schofield E, Bai X, Curry M, Saskin R, Lipitz-Snyderman A, et al. Treatment patterns and outcomes in pancreatic cancer: A comparative analysis of Ontario and the USA. Ann Surg Oncol. 2024;31(1):58\u201365.","journal-title":"Ann Surg Oncol"},{"key":"2440_CR9","doi-asserted-by":"publisher","first-page":"112932.","DOI":"10.1016\/j.ejca.2023.05.020","volume":"189","author":"BK Park","year":"2023","unstructured":"Park BK, Seo JH, Han JH, Lee KJ, Son KJ, Choi JK. Trends in treatment patterns and survival outcomes in pancreatic cancer: a nationwide population-based study in Korea. Eur J Cancer. 2023;189:112932.","journal-title":"Eur J Cancer"},{"key":"2440_CR10","doi-asserted-by":"publisher","first-page":"102230.","DOI":"10.1016\/j.canep.2022.102230","volume":"80","author":"J Kirkegard","year":"2022","unstructured":"Kirkegard J, Bojesen AB, Nielsen MF, Mortensen FV. Trends in pancreatic cancer incidence, characteristics, and outcomes in Denmark 1980-2019. A nationwide cohort study. Cancer Epidemiol. 2022;80:102230.","journal-title":"Cancer Epidemiol"},{"issue":"10","key":"2440_CR11","doi-asserted-by":"publisher","first-page":"3463","DOI":"10.1002\/cam4.3011","volume":"9","author":"Y Doleh","year":"2020","unstructured":"Doleh Y, Lal LS, Blauer-Petersen C, Antico G, Pishvaian M. Treatment patterns and outcomes in pancreatic cancer: retrospective claims analysis. Cancer Med. 2020;9(10):3463\u201376.","journal-title":"Cancer Med"},{"issue":"25","key":"2440_CR12","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","volume":"379","author":"T Conroy","year":"2018","unstructured":"Conroy T, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J. 2018;379(25):2395\u2013406.","journal-title":"N Engl J"},{"issue":"10073","key":"2440_CR13","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/S0140-6736(16)32409-6","volume":"389","author":"JP Neoptolemos","year":"2017","unstructured":"Neoptolemos JP, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017;389(10073):1011\u201324.","journal-title":"Lancet"},{"key":"2440_CR14","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1093\/annonc\/mdv295","volume":"26","author":"M Ducreux","year":"2015","unstructured":"Ducreux M, et al. Cancer of the pancreas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26:56\u201368.","journal-title":"Ann Oncol"},{"key":"2440_CR15","unstructured":"committee Eg. eUpdate - Cancer of the pancreas treatment recommendation esmo. 2019 [updated 15-3-2019. Available from]: https:\/\/www.esmo.org\/guidelines\/gastrointestinal-cancers\/pancreatic-cancer\/eupdate-cancer-of-the-pancreas-treatment-recommendations."},{"key":"2440_CR16","unstructured":"Integraal Kankercentrum Nederland. Zorgpad PACAP-1 acceptatie.oncoguide.nl [Available from: https:\/\/acceptatie.oncoguide.nl\/#!\/projects\/36\/guideline\/350\/tree\/350."},{"issue":"19","key":"2440_CR17","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817\u201325.","journal-title":"N Engl J Med"},{"key":"2440_CR18","doi-asserted-by":"crossref","unstructured":"Goldstein D, et al. Nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. J Natl Cancer Inst. 2015;107(2).","DOI":"10.1093\/jnci\/dju413"},{"issue":"10","key":"2440_CR19","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1002\/ijc.33916","volume":"150","author":"de Jong Ejm","year":"2022","unstructured":"de Jong Ejm, Janssen QP, Simons TFA, Besselink MG, Bonsing BA, Bouwense SAW, et al. Real-world evidence of adjuvant gemcitabine plus capecitabine vs gemcitabine monotherapy for pancreatic ductal adenocarcinoma. Int. J. Cancer. 2022;150(10):1654\u201363.","journal-title":"Int. J. Cancer"},{"issue":"2","key":"2440_CR20","doi-asserted-by":"publisher","first-page":"18.","DOI":"10.1007\/s12032-021-01469-y","volume":"38","author":"O Abdel-Rahman","year":"2021","unstructured":"Abdel-Rahman O, Spratlin J, Koski S. Real-world patterns of adjuvant chemotherapy treatment for patients with resected pancreatic adenocarcinoma. Med Oncol. 2021;38(2):18.","journal-title":"Med Oncol"},{"key":"2440_CR21","doi-asserted-by":"crossref","unstructured":"Badic B, Morvan M, Queneherve L, Bouzeloc S, Kermarrec T, Nousbaum JB, et al. Real world data for pancreatic adenocarcinoma from a population-based study in France. Cancers (Basel). 2023;15(2).","DOI":"10.3390\/cancers15020525"},{"issue":"6","key":"2440_CR22","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3892\/mco.2023.2694","volume":"19","author":"R Shimoyama","year":"2023","unstructured":"Shimoyama R, Imamura Y, Uryu K, Mase T, Fujimura Y, Hayashi M, et al. Real\u2011world treatment outcomes among patients with metastatic pancreatic cancer in Japan: The Tokushukai real\u2011world data project. Mol Clin Oncol. 2023;19(6):98.","journal-title":"Mol Clin Oncol"},{"key":"2440_CR23","doi-asserted-by":"crossref","unstructured":"Park CS, Park BK, Han JH, Lee KJ, Son KJ. Real-world outcomes of first-line chemotherapy in metastatic pancreatic cancer: a nationwide population-based study in Korea. Cancers (Basel). 2024;16(18).","DOI":"10.3390\/cancers16183173"},{"issue":"2","key":"2440_CR24","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1007\/s12029-023-01006-2","volume":"55","author":"BCM Haberkorn","year":"2024","unstructured":"Haberkorn BCM, Hoogendijk L, Loosveld OS, Thijs AMJ, Verstijnen J. Real life data and outcome of FOLFIRINOX use in metastatic pancreatic cancer patients in general hospitals in the Netherlands. J Gastrointest Cancer. 2024;55(2):838\u201344.","journal-title":"J Gastrointest Cancer"},{"issue":"5","key":"2440_CR25","doi-asserted-by":"publisher","first-page":"443","DOI":"10.6004\/jnccn.2021.7028","volume":"20","author":"EN Pijnappel","year":"2021","unstructured":"Pijnappel EN, Dijksterhuis WPM, van der Geest LG, de Vos-Geelen J, de Groot JWB, Homs MYV, et al. First- and second-line palliative systemic treatment outcomes in a real-world metastatic pancreatic cancer cohort. J Natl Compr Canc Netw. 2021;20(5):443\u201350 e3.","journal-title":"J Natl Compr Canc Netw"},{"issue":"6","key":"2440_CR26","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/S1470-2045(16)00172-8","volume":"17","author":"S Mea","year":"2016","unstructured":"Mea S. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. The Lancet Oncol. 2016;17(6):801\u201310.","journal-title":"The Lancet Oncol"},{"key":"2440_CR27","unstructured":"European Society for Medical Oncology. ESMO-MCBS for solid tumors [Available from: https:\/\/www.esmo.org\/guidelines\/esmo-mcbs\/esmo-mcbs-for-solid-tumours."},{"key":"2440_CR28","unstructured":"American Society of Clinical Oncology. Value in Cancer Care. Available from: https:\/\/www.asco.org\/news-initiatives\/current-initiatives\/cancer-care-initiatives\/value-cancer-care."},{"issue":"2","key":"2440_CR29","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.hpb.2019.06.015","volume":"22","author":"M Molinari","year":"2020","unstructured":"Molinari M, El-Tawil K, Swaid F, Fiorentini G, Bou-Samra P, Sharma C, et al. Patients\u2019 treatment preferences for potentially resectable tumors of the head of the pancreas. HPB (oxford). 2020;22(2):265\u201374.","journal-title":"HPB (oxford)"},{"issue":"1","key":"2440_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jval.2015.12.003","volume":"19","author":"P Thokala","year":"2016","unstructured":"Thokala P, et al. Multiple criteria decision analysis for health care decision makin - an introduction: report 1 of the ISPOR MCDA emerging good practices task force. Value Health. 2016;19(1):1\u201313.","journal-title":"Value Health"},{"key":"2440_CR31","unstructured":"NGene [Internet]. choice-metrics.com. 2021."},{"key":"2440_CR32","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jval.2012.08.2223","volume":"16","author":"F Reed Johnson","year":"2013","unstructured":"Reed Johnson F, et al. Constructing experimental designs for discrete-choice experiments: report of the ISPOR conjoint analysis experimental design good research practices task force. Value Health. 2013;16:3\u201313.","journal-title":"Value Health"},{"key":"2440_CR33","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.jval.2016.04.004","volume":"19","author":"A Brett Hauber","year":"2016","unstructured":"Brett Hauber A, et al. Statistical methods for the analysis of discrete choice experiments: a report of the ISPOR conjoint analysis good research practices task force. Value Health. 2016;19:300\u201315.","journal-title":"Value Health"},{"key":"2440_CR34","doi-asserted-by":"crossref","unstructured":"Smith IP, Whichello CL, Veldwijk J, Rutten-van Molken M, Groothuis-Oudshoorn CGM, Vos RC, et al. Diabetes patient preferences for glucose-monitoring technologies: results from a discrete choice experiment in Poland and the Netherlands. BMJ Open Diabetes Res Care. 2023;11(1).","DOI":"10.1136\/bmjdrc-2022-003025"},{"issue":"3","key":"2440_CR35","doi-asserted-by":"publisher","first-page":"e056741","DOI":"10.1136\/bmjopen-2021-056741","volume":"13","author":"M Bao","year":"2023","unstructured":"Bao M, Huang C, Wang L, Yan G, Chen G. Eliciting primary healthcare physicians\u2019 preferences for job characteristics in rural China: a discrete choice experiment. BMJ Open. 2023;13(3):e056741.","journal-title":"BMJ Open"},{"key":"2440_CR36","unstructured":"Castor. 2024 [2024-09-22]. Available from: https:\/\/www.castoredc.com\/electronic-data-capture-system\/."},{"issue":"3","key":"2440_CR37","doi-asserted-by":"publisher","first-page":"e196","DOI":"10.1097\/AS9.0000000000000196","volume":"3","author":"J Trobaugh","year":"2022","unstructured":"Trobaugh J, Fuqua W, Folkert K, Khalil S, Shebrain S, Munene G. Shared decision-making in pancreatic surgery. Ann Surg Open. 2022;3(3):e196.","journal-title":"Ann Surg Open"},{"issue":"19","key":"2440_CR38","doi-asserted-by":"publisher","first-page":"20119","DOI":"10.1002\/cam4.6590","volume":"12","author":"YL Tseng","year":"2023","unstructured":"Tseng YL, Lin YC, Hsu WJ, Kang YC, Su HY, Cheng SY, et al. Shared decision making with oncologists and palliative care specialists (SOP) model help advanced pancreatic cancer patients reaching goal concordant care: a prospective cohort study. Cancer Med. 2023;12(19):20119\u201328.","journal-title":"Cancer Med"},{"key":"2440_CR39","unstructured":"Alvleesklierkanker keuzehulp 2023[Available from]: https:\/\/ak.keuzehulp.nl\/over-keuzehulp."},{"issue":"5","key":"2440_CR40","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s40271-023-00635-w","volume":"16","author":"A Livingstone","year":"2023","unstructured":"Livingstone A, Howard K, Menzies AM, Long GV, Stockler MR, Morton RL. Preferences for adjuvant immunotherapy in adults with resected stage III melanoma-A discrete choice experiment. Patient-Patient Centered Outcomes Res. 2023;16(5):497\u2013513.","journal-title":"Patient-Patient Centered Outcomes Res"},{"key":"2440_CR41","volume-title":"Patient preferences for metastatic colorectal cancer treatment: a multi-method approach using discrete choice experiments and best-worst scaling","author":"C Oedingen","year":"2025","unstructured":"Oedingen C, MacDonald KV, Stein BD, Batist G, Cheung WY, Gill S, et al. Patient preferences for metastatic colorectal cancer treatment: a multi-method approach using discrete choice experiments and best-worst scaling. Patient-Patient Centered Outcomes Research; 2025."},{"issue":"6","key":"2440_CR42","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s40271-023-00638-7","volume":"16","author":"JM Gonzalez","year":"2023","unstructured":"Gonzalez JM, Ganguli A, Morgans AK, Tombal BF, Hotte SJ, Suzuki H, et al. Discrete-choice experiment to understand the preferences of patients with hormone-sensitive prostate cancer in the USA, Canada, and the UK. Patient-Patient Centered Outcomes Res. 2023;16(6):607\u201323.","journal-title":"Patient-Patient Centered Outcomes Res"},{"issue":"6","key":"2440_CR43","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/s10198-014-0622-4","volume":"16","author":"AC M\u00fchlbacher","year":"2015","unstructured":"M\u00fchlbacher AC, Bethge S. Patients\u2019 preferences: a discrete-choice experiment for treatment of non-small-cell lung cancer. Eur J Health Econ. 2015;16(6):657\u201370.","journal-title":"Eur J Health Econ"},{"issue":"1","key":"2440_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jval.2015.12.003","volume":"19","author":"P Thokala","year":"2016","unstructured":"Thokala P, Devlin N, Marsh K, Baltussen R, Boysen M, Kalo Z, et al. Multiple criteria decision analysis for health care decision making-an introduction: report 1 of the ISPOR MCDA emerging good practices task force. Value Health. 2016;19(1):1\u201313.","journal-title":"Value Health"},{"key":"2440_CR45","doi-asserted-by":"crossref","unstructured":"Pihlak R, Frizziero M, Mak SYG, Nuttall C, Lamarca A, Hubner RA, et al. Relevant study: patient and clinician perspectives on clinically-meaningful outcomes in advanced pancreatic cancer. Cancers (Basel). 2023;15(3).","DOI":"10.3390\/cancers15030738"},{"issue":"12","key":"2440_CR46","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1016\/0959-8049(95)00513-7","volume":"31A","author":"RM Bremnes","year":"1995","unstructured":"Bremnes RM, Andersen K, Wist EA. Cancer patients, doctors and nurses vary in their willingness to undertake cancer chemotherapy. Eur J Cancer. 1995;31A(12):1955\u201359.","journal-title":"Eur J Cancer"},{"issue":"12","key":"2440_CR47","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1054\/bjoc.2001.1836","volume":"84","author":"SJ Jansen","year":"2001","unstructured":"Jansen SJ, Kievit J, Nooij MA, de Haes JC, Overpelt IM, van Slooten H, et al. Patients\u2019 preferences for adjuvant chemotherapy in early-stage breast cancer: is treatment worthwhile? Br J Cancer. 2001;84(12):1577\u201385.","journal-title":"Br J Cancer"},{"issue":"5","key":"2440_CR48","doi-asserted-by":"publisher","first-page":"6040","DOI":"10.1002\/cam4.5313","volume":"12","author":"DJ George","year":"2023","unstructured":"George DJ, Mohamed AF, Tsai JH, Karimi M, Ning N, Jayade S, et al. Understanding what matters to metastatic castration-resistant prostate cancer (mCRPC) patients when considering treatment options: a US patient preference survey. Cancer Med-Us. 2023;12(5):6040\u201355.","journal-title":"Cancer Med-Us"},{"issue":"12","key":"2440_CR49","doi-asserted-by":"publisher","first-page":"3459","DOI":"10.1002\/cncr.23968","volume":"113","author":"NJ Meropol","year":"2008","unstructured":"Meropol NJ, Egleston BL, Buzaglo JS, Benson AB 3rd, Cegala DJ, Diefenbach MA, et al. Cancer patient preferences for quality and length of life. Cancer. 2008;113(12):3459\u201366.","journal-title":"Cancer"},{"key":"2440_CR50","doi-asserted-by":"crossref","unstructured":"Richards MA, Ramirez AJ, Degner LF, Fallowfield LJ, Maher EJ, Neuberger J. Offering choice of treatment to patients with cancers. A review based on a symposium held at the 10th annual conference of the British psychosocial oncology group. Eur J Cancer. 1993. 1995, December;31A(1):112\u20136.","DOI":"10.1016\/0959-8049(94)00478-N"},{"issue":"10","key":"2440_CR51","doi-asserted-by":"publisher","first-page":"E217","DOI":"10.1503\/cmaj.151171","volume":"188","author":"C Zimmermann","year":"2016","unstructured":"Zimmermann C, Swami N, Krzyzanowska M, Leighl N, Rydall A, Rodin G, et al. Perceptions of palliative care among patients with advanced cancer and their caregivers. CMAJ. 2016;188(10):E217\u201327.","journal-title":"CMAJ"},{"issue":"27","key":"2440_CR52","doi-asserted-by":"publisher","first-page":"4479","DOI":"10.1200\/JCO.2006.06.0269","volume":"24","author":"M Agrawal","year":"2006","unstructured":"Agrawal M, Grady C, Fairclough DL, Meropol NJ, Maynard K, Emanuel EJ. Patients\u2019 decision-making process regarding participation in phase I oncology research. J Clin Oncol. 2006;24(27):4479\u201384.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2440_CR53","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/1467-9566.00081","volume":"20","author":"C Charles","year":"1998","unstructured":"Charles C, Redko C, Whelan T, Gafni A, Reyno L. Doing nothing is no choice: lay constructions of treatment decision-making among women with early-stage breast cancer. Sociol Health Ill. 1998;20(1):71\u201395.","journal-title":"Sociol Health Ill"},{"issue":"18","key":"2440_CR54","doi-asserted-by":"publisher","first-page":"4571","DOI":"10.1002\/cncr.27397","volume":"118","author":"RD Pentz","year":"2012","unstructured":"Pentz RD, White M, Harvey RD, Farmer ZL, Liu Y, Lewis C, et al. Therapeutic misconception, misestimation, and optimism in participants enrolled in phase 1 trials. Cancer. 2012;118(18):4571\u201378.","journal-title":"Cancer"},{"issue":"5","key":"2440_CR55","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1002\/pon.5675","volume":"30","author":"EA Finkelstein","year":"2021","unstructured":"Finkelstein EA, Baid D, Cheung YB, Schweitzer ME, Malhotra C, Volpp K, et al. Hope, bias and survival expectations of advanced cancer patients: A cross-sectional study. Psychooncology. 2021;30(5):780\u201388.","journal-title":"Psychooncology"},{"issue":"8","key":"2440_CR56","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1002\/cncr.29908","volume":"122","author":"LA Jansen","year":"2016","unstructured":"Jansen LA, Mahadevan D, Appelbaum PS, Klein WM, Weinstein ND, Mori M, et al. Dispositional optimism and therapeutic expectations in early-phase oncology trials. Cancer. 2016;122(8):1238\u201346.","journal-title":"Cancer"},{"issue":"6","key":"2440_CR57","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1177\/1090198113477109","volume":"40","author":"JD Jensen","year":"2013","unstructured":"Jensen JD, Scherr CL, Brown N, Jones C, Christy K. Public perception of cancer survival rankings. Health Educ Behav. 2013;40(6):721\u201329.","journal-title":"Health Educ Behav"},{"key":"2440_CR58","doi-asserted-by":"crossref","unstructured":"Sundaresan TK, Evans NS, Gupta S, Leung L, Lee J, Wong M, et al. Treatment rates and reasons for non-treatment in a real-world cohort of patients with pancreatic cancer. J Clin Oncol. 2024;42(16).","DOI":"10.1200\/JCO.2024.42.16_suppl.e13554"},{"issue":"9","key":"2440_CR59","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1080\/0284186X.2018.1470330","volume":"57","author":"M Zijlstra","year":"2018","unstructured":"Zijlstra M, van der Geest LGM, van Laarhoven HWM, Lemmens V, van de Poll-Franse LV, Raijmakers NJH. Patient characteristics and treatment considerations in pancreatic cancer: a population based study in the Netherlands. Acta Oncol. 2018;57(9):1185\u201391.","journal-title":"Acta Oncol"},{"issue":"9","key":"2440_CR60","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1038\/bjc.1996.570","volume":"74","author":"MH Cullen","year":"1996","unstructured":"Cullen MH, Billingham LJ, Cook J, Woodroffe CM. Management preferences in stage I non-seminomatous germ cell tumours of the testis: an investigation among patients, controls and oncologists. Br J Cancer. 1996;74(9):1487\u201391.","journal-title":"Br J Cancer"},{"issue":"4","key":"2440_CR61","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1200\/JCO.1998.16.4.1380","volume":"16","author":"C Lindley","year":"1998","unstructured":"Lindley C, Vasa S, Sawyer WT, Winer EP. Quality of life and preferences for treatment following systemic adjuvant therapy for early-stage breast cancer. J Clin Oncol. 1998;16(4):1380\u201387.","journal-title":"J Clin Oncol"},{"issue":"3","key":"2440_CR62","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/S0015-0282(98)00213-1","volume":"70","author":"PT Nieuwkerk","year":"1998","unstructured":"Nieuwkerk PT, Hajenius PJ, Van der Veen F, Ankum WM, Wijker W, Bossuyt PM. Systemic methotrexate therapy versus laparoscopic salpingostomy in tubal pregnancy. Part II. Patient preferences for systemic methotrexate. Fertil Steril. 1998;70(3):518\u201322.","journal-title":"Fertil Steril"},{"issue":"8","key":"2440_CR63","doi-asserted-by":"publisher","first-page":"5051","DOI":"10.1245\/s10434-023-13465-9","volume":"30","author":"S Augustinus","year":"2023","unstructured":"Augustinus S, Schafrat PJM, Janssen BV, Bonsing BA, Brosens LAA, Busch OR, et al. Nationwide impact of centralization, neoadjuvant therapy, minimally invasive surgery, and standardized pathology reporting on R0 resection and overall survival in pancreatoduodenectomy for pancreatic cancer. Ann Surg Oncol. 2023;30(8):5051\u201360.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"2440_CR64","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s12029-016-9902-9","volume":"48","author":"V Picozzi","year":"2017","unstructured":"Picozzi V, Narayanan S, Henry Hu X, Vacirca J. Health-related quality of life in patients with metastatic pancreatic cancer. J Gastrointest Cancer. 2017;48(1):103\u201309.","journal-title":"J Gastrointest Cancer"},{"key":"2440_CR65","doi-asserted-by":"publisher","first-page":"4805","DOI":"10.2147\/CMAR.S166713","volume":"10","author":"X Zhu","year":"2018","unstructured":"Zhu X, Li F, Shi D, Ju X, Cao Y, Shen Y, et al. Health-related quality of life for gemcitabine and nab-paclitaxel plus radiotherapy versus gemcitabine and S-1 plus radiotherapy in patients with metastatic pancreatic cancer. Cancer Manag Res. 2018;10:4805\u201315.","journal-title":"Cancer Manag Res"},{"issue":"1","key":"2440_CR66","first-page":"7","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7\u201333.","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"2440_CR67","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1200\/JCO.21.02233","volume":"40","author":"E Versteijne","year":"2022","unstructured":"Versteijne E, van Dam JL, Suker M, Janssen QP, Groothuis K, Akkermans-Vogelaar JM, et al. Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: long-term results of the Dutch randomized PREOPANC trial. J Clin Oncol. 2022;40(11):1220\u201330.","journal-title":"J Clin Oncol"}],"container-title":["Health and Quality of Life Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12955-025-02440-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12955-025-02440-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12955-025-02440-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T11:02:17Z","timestamp":1766574137000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12955-025-02440-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,24]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2440"],"URL":"https:\/\/doi.org\/10.1186\/s12955-025-02440-5","relation":{},"ISSN":["1477-7525"],"issn-type":[{"type":"electronic","value":"1477-7525"}],"subject":[],"published":{"date-parts":[[2025,12,24]]},"assertion":[{"value":"16 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The PERSEUS study was reviewed by the institutional medical ethical committee of the Amsterdam UMC and declared to be not subject to the Dutch Medical Research Involving Human Subjects Act (2021.0362). The study was conducted according to the Declaration of Helsinki. All participants gave written informed consent. The use of Castor EDC software was in line with the European Union\u2019s General Data Protection Regulation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"HWMvL reports an advisory role for AMphera, Anocca, Astellas, AstraZeneca, Beigene, Boehringer, Daiichy-Sankyo, Dragonfly, Eli Lilly, MSD, Myeloid, Nordic Pharma, Servier, has received research funding, medication supply and\/or research support from Auristone, Bayer, BMS, Celgene, Eli Lilly, Janssen, Incyte, Merck, MSD, Nordic Pharma, ORCA, Philips, Roche and Servier, and has had a speaker role at Astellas, Beigene, Benecke, BMS, Daiichy-Sankyo, JAAP, Medtalks, Novartis, Springer, Travel Congress Management BV. All fees were paid to the institution. MFB has received research funding from Celgene, Frame Therapeutics, and Lead Pharma, and has acted as a consultant to Servier, Olympus and Wholomics. JWW reports an advisory role for MSD, Astra Zeneca and Servier, and has received grants of MSD, Servier and Nordic. MGB has received research funding from Intuitive Surgical, Oncosil, Medtronic, and Ethicon. JdVG has served as a consultant for Amgen, AstraZeneca, MSD, Pierre Fabre, and Servier, and has received institutional research funding from Servier. All outside the submitted work. MFL, IPS, ENvA, SA, IJMF, IQM, MYVH, IHJTdH, BAB, BCH, PAJV, PTN, and GWJF report no conflicts of interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"122"}}